Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Selexis has partnered with the National Research Counsel of Canada's Biological Research Institute to offer the NRC-BRI HEK293 cell technologies for the contract development of high-performance stable human cell lines enabled by the Selexis Genetic Element and Selexis Sure Cell Line development services.
Subscribe to our email newsletter
According to the company, HEK293 cells are the most widely used human cell line in biotechnology industry and the only human cell line used for the bioproduction of an FDA approved biopharmaceutical drug.
Pierre-Alain Girod, CSO of Selexis, said: “This combined program will be highly desirable to biotech companies needing the rapid development of a high performance cell line expressing proteins with human glycosylation patterns. This new platform will be a viable option to our CHO program for more difficult to express proteins.”